56.02
0.39%
+0.225
Catalent Inc. stock is currently priced at $56.02, with a 24-hour trading volume of 2.30M.
It has seen a +0.39% increased in the last 24 hours and a -0.43% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $55.90 pivot point. If it approaches the $56.04 resistance level, significant changes may occur.
Previous Close:
$55.80
Open:
$55.88
24h Volume:
2.30M
Market Cap:
$10.11B
Revenue:
$4.10B
Net Income/Loss:
$-1.30B
P/E Ratio:
-43.10
EPS:
-1.3
Net Cash Flow:
$-263.00M
1W Performance:
+0.97%
1M Performance:
-0.43%
6M Performance:
+42.65%
1Y Performance:
+28.10%
Catalent Inc. Stock (CTLT) Company Profile
Name
Catalent Inc.
Sector
Phone
732-537-6200
Address
14 Schoolhouse Road, Somerset, NJ
Catalent Inc. Stock (CTLT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-16-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
Sep-05-23 | Upgrade | Argus | Hold → Buy |
Jul-20-23 | Initiated | Wells Fargo | Equal Weight |
Jul-05-23 | Resumed | JP Morgan | Neutral |
Jun-14-23 | Downgrade | Jefferies | Buy → Hold |
May-22-23 | Downgrade | JP Morgan | Overweight → Neutral |
May-15-23 | Downgrade | Deutsche Bank | Buy → Hold |
May-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
Apr-17-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
Apr-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
Apr-10-23 | Upgrade | Deutsche Bank | Hold → Buy |
Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
Dec-19-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Nov-07-22 | Downgrade | Argus | Buy → Hold |
Nov-02-22 | Downgrade | BofA Securities | Buy → Neutral |
Dec-16-21 | Initiated | Barclays | Overweight |
Dec-10-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Jun-25-20 | Initiated | Argus | Buy |
Apr-21-20 | Initiated | RBC Capital Mkts | Outperform |
Mar-02-20 | Initiated | Deutsche Bank | Hold |
Oct-17-19 | Resumed | Stephens | Overweight |
Aug-28-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Jun-21-19 | Upgrade | Jefferies | Hold → Buy |
Apr-16-19 | Upgrade | UBS | Neutral → Buy |
Nov-07-18 | Upgrade | First Analysis Sec | Neutral → Outperform |
Oct-09-18 | Initiated | UBS | Neutral |
Mar-28-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
Mar-21-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
Feb-06-18 | Downgrade | Stephens | Overweight → Equal-Weight |
Sep-21-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-13-17 | Initiated | Needham | Hold |
Sep-08-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
Dec-01-16 | Initiated | Goldman | Neutral |
Oct-20-16 | Initiated | KeyBanc Capital Mkts | Overweight |
Jun-21-16 | Upgrade | Wells Fargo | Market Perform → Outperform |
Jun-20-16 | Upgrade | BofA/Merrill | Neutral → Buy |
View All
Catalent Inc. Stock (CTLT) Latest News
TAK or CTLT: Which Is the Better Value Stock Right Now?
Zacks Investment Research
Charles River (CRL) Forges Collaboration With Ship of Theseus
Zacks Investment Research
Beyond The Numbers: 6 Analysts Discuss Catalent Stock
Benzinga
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
The Motley Fool
Did Novo Nordisk Just Get a Jump on Eli Lilly?
The Motley Fool
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Zacks Investment Research
Catalent Inc. Stock (CTLT) Financials Data
Catalent Inc. (CTLT) Revenue 2024
CTLT reported a revenue (TTM) of $4.10 billion for the quarter ending December 31, 2023, a -13.38% decline year-over-year.
Catalent Inc. (CTLT) Net Income 2024
CTLT net income (TTM) was -$1.30 billion for the quarter ending December 31, 2023, a -433.85% decrease year-over-year.
Catalent Inc. (CTLT) Cash Flow 2024
CTLT recorded a free cash flow (TTM) of -$263.00 million for the quarter ending December 31, 2023, a +29.11% increase year-over-year.
Catalent Inc. (CTLT) Earnings per Share 2024
CTLT earnings per share (TTM) was -$7.06 for the quarter ending December 31, 2023, a -412.39% decline year-over-year.
Catalent Inc. Stock (CTLT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Gunther Scott | SVP, Quality & Reg. Affairs |
Mar 15 '24 |
Sale |
56.20 |
387 |
21,749 |
29,506 |
Ryan Michelle R | Director |
Aug 31 '23 |
Buy |
49.98 |
1,000 |
49,980 |
1,979 |
GREISCH JOHN J | Executive Chair |
Aug 30 '23 |
Buy |
50.24 |
21,000 |
1,055,040 |
34,000 |
Maselli Alessandro | President & CEO |
Aug 24 '23 |
Sale |
44.54 |
2,071 |
92,245 |
88,004 |
Fasman Steven L | EVP & Chief Admin Officer |
Aug 24 '23 |
Sale |
44.65 |
817 |
36,479 |
73,789 |
Gennadios Aristippos | Group Pres. Pharma & Consumer |
Aug 24 '23 |
Sale |
44.49 |
396 |
17,618 |
96,552 |
Grippo Michael J | SVP, Strategy & Corp. Dev. |
Aug 24 '23 |
Sale |
44.50 |
390 |
17,355 |
24,449 |
Pravda Ricardo | Chief Transformation Officer |
Aug 24 '23 |
Sale |
44.47 |
379 |
16,854 |
30,224 |
Hopson Ricky | Pres. Clinical Dev Supply Div |
Aug 24 '23 |
Sale |
44.56 |
276 |
12,299 |
22,040 |
Gunther Scott | SVP, Quality & Reg. Affairs |
Aug 24 '23 |
Sale |
44.57 |
269 |
11,989 |
29,932 |
About Catalent Inc.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Cap:
|
Volume (24h):